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Abstract
Summary This case–control study showed that current use
of conventional antipsychotics, but not atypical antipsy-
chotics, seems to be associated with an increased risk of a
hip/femur fracture, possibly related to the pharmacological
properties of conventional antipsychotics. Furthermore, no
evidence for a dose effect was found.
Introduction The aim of this study was to assess the risk of
hip/femur fracture associated with antipsychotic use, with
particular reference to any difference in risk with conven-
tional versus atypical antipsychotics, dose, and pharmaco-
logical properties.
Methods A case–control study was conducted using data
from the PHARMO Record Linkage System among indi-
viduals aged 18 years and older between 1991 and 2002.
Cases had a record of a hip or femur fracture, while controls
had no evidence of ever having sustained any fracture.
Results Most cases were elderly (77.6% aged ≥70 years).
We found an increased risk for hip/femur fracture associ-
ated with the use of antipsychotic drugs. The risk for
current users (ORadj 1.68 [1.43, 1.99]) was significantly
greater than with past use (ORadj 1.33 [1.14, 1.56]; p=
0.036). Current use of conventional antipsychotics (ORadj
1.76 [1.48, 2.08]) but not atypical antipsychotics (ORadj
0.83 [0.42, 1.65]) was associated with an increased risk. We
did not find evidence for a dose effect.
Conclusion The use of conventional, but not atypical
antipsychotics, seems to be associated with an increased
risk of hip/femur fracture, possibly related to the pharma-
cological properties of conventional antipsychotics. How-
ever, the numbers of atypical antipsychotic users were
small, and therefore this observation needs further attention
in other study populations.
Keywords Antipsychotics . Bone density . Fracture .
Osteoporosis . Risk factors
Introduction
Antipsychotics are common in the treatment of schizophrenia,
affective disorders, organic psychosis, and dementia [1, 2].
The side effects associated with antipsychotic use include
sedation, extrapyramidal symptoms (EPS), and orthostatic
hypertension, all of which may increase the risk of falls,
especially during the initial period of exposure [3]. Conven-
tional antipsychotics (e.g., haloperidol, chlorpromazine) and
the atypical antipsychotic risperidone at high dose have a
high affinity for dopamine D2 receptors [4]. This pharmaco-
logical property is clearly associated with the risk of EPS but
also gives rise to elevated prolactin levels [5, 6]. In contrast,
most atypical antipsychotics like clozapine, olanzapine,
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quetiapine, and low-dose risperidone have a higher affinity
for the 5-hydroxytryptamine-2A (5-HT2A) receptor than for
dopamine D2 receptors [4]. Blocking of the 5-HT2A receptor
has been associated with lowered prolactin levels. In
contrary, the stimulating of 5-HT2A receptors has been
linked to increased prolactin levels [7]. The latter is the case
when using a selective serotonin reuptake inhibitor (SSRI).
Elevated serum prolactin may reduce bone mineral
density (BMD) in the long-term [6, 8, 9]. O’Keane and
Meaney [10] found that the BMD of patients using
prolactin-raising antipsychotics was significantly lower
than that of users of antipsychotics without prolactin-raising
properties. In line with these results are the findings that
patients using SSRIs also experience a lower BMD [11] and
have an increased risk of fracture [12].
Several epidemiological studies have reported an in-
creased risk of hip or femur fracture among users of
antipsychotics [13–19]. One study found a relationship
between dose and use of antipsychotics, regardless of timing
of exposure, although this was not reported for current users
[17]. Liperoti et al. found no difference in fracture risk
between conventional and atypical antipsychotics [15],
whereas Howard et al. found an increased risk for individuals
using prolactin-raising antipsychotics [13]. In addition, there
is some evidence to suggest that men using antipsychotics
have a greater risk of fracture than women [13].
The aims of this study were to evaluate the association
between the use of antipsychotics and the risk of fracture of
the hip or femur for men and women, to derive risk
estimates separately for conventional and atypical antipsy-
chotics, and to investigate the risk associated with dose and
pharmacological properties.
Methods
Setting and study design
We conducted a case–control study within the Dutch
PHARMO Record Linkage System (RLS) (www.pharmo.nl).
The database includes the demographic details and com-
plete medication histories for about one million communi-
ty-dwelling residents in the Netherlands representing some
7% of the general population. Data are available from 1986
onwards and are linked to hospital discharge records as
well as several other health registries, including pathology,
clinical laboratory findings, and general practitioner data.
Almost every individual in the Netherlands is registered
with a single community pharmacy, independent of
prescriber and irrespective of his or her health insurance
or socioeconomic status. Pharmacy records have a high
degree of completeness with regard to dispensed drugs
[20]. Pharmacy data include information about the drug
dispensed, the date of dispensing, the prescriber, the
amount dispensed, the prescribed dosage regimen, and
the estimated duration of use. Hospital discharge records
include detailed information on date of admission, dis-
charge diagnoses, and procedures. Validation studies on
PHARMO RLS have confirmed a high level of data
completeness and validity with regards to fractures [21];
PHARMO has been used more often to address risk factors
of hip/femur fracture risk [22–24].
Study population
Data were collected for the period 1 January 1991 to 31
December 2002. Cases were patients aged 18 years and
older with a record for a first fracture of the hip or femur
during the study period. The date of hospital admission was
used to define the index date. Each case was matched by
year of birth, sex, and geographical region to up to four
control patients without any evidence of ever having
sustained a fracture during data collection. The controls
were assigned the same index date as the corresponding
case.
Exposure assessment
Exposure to antipsychotics (Anatomical and Therapeutic
Chemical [ATC] category N05A excluding lithium [25])
was determined by reviewing dispensing information before
the index date. “Current” users were patients who had been
dispensed at least one antipsychotic within the 30-day period
before the index date. “Recent” users were those who had
been dispensed an antipsychotic between 31 and 182 days
before the index date. “Past” users were patients who had
one or more dispensings for an antipsychotic but who had
stopped treatment more than 182 days before the index date.
For each current user, the average daily dose was
estimated by dividing the total amount of antipsychotics
dispensed by the treatment time. Average daily doses were
expressed in haloperidol equivalents using defined daily
dosages [25]. The duration of continuous use was
calculated using the expected duration of use (in days)
for each dispensing (the dispensed amount of the drug
divided by the recorded dosage instruction). The total
exposure period was defined as the sum of the total
expected durations of use from all dispensings. If the
period between two antipsychotic dispensings exceeded
6 months, this was considered a gap in treatment. Drugs
dispensed before the gap were not included when
calculating the period of continuous use.
Antipsychotic drugs were classified as atypical (quetia-
pine, clozapine, risperidone, olanzapine) or conventional
(pipamperone, haloperidol, zuclopenthixol, thioridazine,
levomepromazine, and “others”; Table 1). The most
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recently dispensed antipsychotic was used to define the
type. When more than one dispensing was issued, all
dispensings were taken into account.
Among current users we assessed the sedative, extrapy-
ramidal, prolactin-raising, and orthostatic hypotensive
pharmacological properties of the antipsychotic dispensed
as determined by an extensive review of the literature [1, 4,
6, 26–32] (Table 1). If more than one antipsychotic had
been prescribed before the index date, we selected the drug
with the most severe side effect profile.
Potential confounders
The records of cases and controls were reviewed for
evidence of potential confounders that have been associated
with fracture risk [33, 34]. These included a recent history
(in the previous year) of anemia, mental disorders, impaired
renal function, injuries, and skin or subcutaneous diseases
and a history at any time of malignant neoplasm, endocrine
disorder, cardiovascular disease, cerebrovascular disease,
obstructive airway disease, inflammatory bowel disease,
musculoskeletal or connective tissue disease, rheumatoid
arthritis, polymyalgia rheumatica or ankylosing spondylitis.
Other potential confounders included a dispensing within
3 months before the index date of a benzodiazepine or a
prescription within the previous 6 months for any of the
following: eye drops, bronchodilators, inhaled or oral cortico-
steroids, statins, hormone replacement therapy, lithium,
antidepressants, beta-blockers, opioids, antiarrythmics, anti-
epileptics, thiazide diuretics, renin–angiotensin–aldosterone
system (RAAS) inhibitors, thyroid and antithyroid hormones,
drugs for diabetes, disease-modifying antirheumatic drugs
(DMARDs), metoclopramide, 5HT3 antagonists, and two or
more prescriptions for a non-steroidal antiinflammatory drug
(NSAID).
Statistical analysis
Odds ratios (ORs) were derived for the risk of hip/femur
fracture associated with the use of antipsychotics and the
various potential confounding variables. Adjusted odds
ratios (ORadj) for hip/femur fracture were estimated by
comparing antipsychotic use with no use determined by
conditional logistic regression analysis. Final regression
Table 1 Categorization of antipsychotic drugs and side effect profiles
Group Generic name properties Sedative properties EPS properties Prolactin properties OH
Atypical Clozapine High Low Non-raising High
Olanzapine Medium Low Non-raising Medium
Quetiapine Medium Low Non-raising Medium
Risperidone Medium Medium – Medium
Risperidone ≤4 mg/day – – Non-raising –
Risperidone >4 mg/day – – Raising –
Conventional Haloperidol Low High Raising Low
Levomepromazine High Medium Raising Medium
Pipamperone High Low Raising Medium
Thioridazine High Low Raising High
Zuclopenthixol Medium Medium Raising High
Other conventional Benperidol High Low Raising Low
Bromperidol Low High Raising Low
Chlorpromazine High Medium Raising High
Chlorprothixene Medium Medium Raising High
Droperidol Medium Medium Raising Medium
Flupentixol Low Medium Raising Medium
Fluphenazine Low High Raising Medium
Fluspirilene Low Medium Raising Medium
Penfluridol High Medium Raising Low
Perazine High Low Raising High
Periciazine High Medium Raising Medium
Perphenazine Medium Medium Raising Low
Pimozide Low Medium Raising Low
Prochlorperazine Medium High Raising Medium
Sulpiride Low Medium Raising Low
Tiapride Low Low Raising Low
Trifluoperazine Low High Raising Low
OH orthostatic hypotension
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models were determined by stepwise backward elimination
using a significance level of 0.05. Significant differences
between categories were determined with the Wald statistic
option of the PHREG procedure of SAS 9.1.
Analyses were conducted to evaluate the risk of fracture
associated with current exposure to antipsychotics versus
no use, grouping current users according to the daily dose
of antipsychotic prescribed, whether the antipsychotic
prescribed was conventional or atypical and according to
the severity of expected side effects. We also stratified the
study population to assess the risk with current use by age
and sex.
Results
Table 2 shows the baseline characteristics of cases and
controls. We identified 6,763 cases with a fracture of the
hip or femur and 26,341 matched controls. Almost three-
quarters (73%) of the study population was female. The
mean duration of follow-up before the index date was
5.8 years for cases and 5.7 years for controls. The median
age was 79 years for cases and controls. The median
duration of use for current users was 30 days (determined
from 94% of current users).
The use of antipsychotic drugs by cases and controls and
the results of conditional logistic regression analysis are
presented in Table 3. Antipsychotic drug use was signifi-
cantly higher among cases compared with controls, with a
trend towards increased risk of hip/femur fracture with
recency of use. Current use of antipsychotics was associ-
Table 3 Risk of hip/femur fracture with antipsychotic use versus no use, including risk estimates (derived by conditional logistic regression
analysis) for current use overall and by daily dose, and for current use by sex and age group
Antipsychotic usea Cases Controls Univariate analysis Multivariate analysisb
(n=6,763) (n=26,341) OR (95% CI) OR (95% CI)
No use 6,105 24,770 Referent Referent
Past use 249 653 1.57 (1.35, 1.83) 1.33 (1.14, 1.56)c
Recent use 172 425 1.63 (1.36, 1.96) 1.38 (1.15, 1.66)
Current use 237 493 2.00 (1.70, 2.35) 1.68 (1.43, 1.99)c
By average daily dose, mg/dayd
First time users 71 150 1.98 (1.48, 2.63) 1.60 (1.19, 2.15)
<0.8 60 122 2.04 (1.49, 2.79) 1.79 (1.30, 2.47)
0.8–1.9 60 126 2.01 (1.47, 2.75) 1.66 (1.20, 2.30)
≥2 46 95 1.96 (1.37, 2.80) 1.71 (1.19, 2.46)
By gender
Females 193 419 1.90 (1.59, 2.27) 1.63 (1.36, 1.96)
Males 44 74 2.53 (1.72, 3.72) 1.93 (1.28, 2.90)
By age category
Ages 18–69 years 15 35 1.78 (0.97, 3.28) 0.95 (0.48, 1.87)
Ages ≥70 years 222 458 2.00 (1.69, 2.37) 1.74 (1.46, 2.06)
a For current, recent, and past users, the last antipsychotic was dispensed respectively within 30 days, between 31 and 182 days, and more than
182 days prior to the index date
b Adjusted for a history of malignant neoplasm, anemia, endocrine disorders, skin or subcutaneous disease, cerebrovascular disease, obstructive
airway disease, musculoskeletal or connective tissue disease, use of benzodiazepines, inhaled or oral glucocorticoids, statins, antidepressants,
beta-blockers, opioids, antiepileptics, RAAS inhibitors, drugs for diabetics, DMARDs, metoclopramide, and two or more NSAID dispensing
c Significant difference between current and past use of antipsychotics (p=0.036 after Wald test)
d Haloperidol equivalents
Table 2 Characteristics of cases and controls
Characteristic Cases (%) Controls (%)
(n=6,763) (n=26,341)
Age (years)
18–49 452 (6.7) 1,808 (6.9)
50–69 1,061 (15.7) 4,239 (16.1)
≥70 5,250 (77.6) 20,294 (77.0)
Number of females 4,929 (72.9) 19,138 (72.7)
Medical history
Rheumatoid arthritis 353 (5.2) 1,108 (4.2)
Cardiovascular disease 359 (5.3) 1,289 (4.9)
Malignant neoplasm 391 (5.8) 1,021 (3.9)
Inflammatory bowel disease 361 (5.3) 921 (3.5)
Cerebrovascular disease 296 (4.4) 565 (2.1)
Drug use in 6 months before index date
Oral glucocorticoids 366 (5.4) 918 (3.5)
DMARDs 115 (1.7) 202 (0.8)
Antidepressants 643 (9.5) 1,343 (5.1)
Anxiolytics 1,170 (17.3) 3,451 (13,1)
Antiepileptics 494 (7.3) 938 (3.6)
Lithium 18 (0.3) 34 (0.1)
Hormone replacement therapy 77 (1.1) 347 (1.3)
Bisphosphonates 261 (3.9) 616 (2.3)
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ated with a significantly increased risk of hip/femur fracture
compared with no use (ORadj 1.68 [95% CI 1.43, 1.99]) and
the risk associated with current use was significantly greater
than that associated with past use (ORadj 1.33 [95% CI
1.14, 1.56]; p=0.036). When current use was defined by
daily dose, the risk estimates for fracture did not demon-
strate a dose–response relationship. Further stratified
analyses suggested that the risk of hip/femur fracture for
current users of antipsychotics was greater for men (ORadj
1.93 [95% CI 1.28, 2.90]) than for women (ORadj 1.63
[95% CI 1.36, 1.96]), although not significantly so.
Similarly, risk was increased for individuals aged ≥70 years
(ORadj 1.74 [95% CI 1.46, 2.06]), but not for younger
patients (ORadj 0.95 [95% CI 0.48, 1.87]).
Figure 1 presents ORs for hip/femur fracture with
duration of continuous use before the index date among
current users. There was a marked increase in fracture risk
during the first 8 months of continuous antipsychotic use
(ORadj 2.83 [95% CI 1.75, 4.57]) and evidence to suggest a
second period of increased risk as the duration of
continuous use approached 2 years.
The current use of atypical antipsychotics did not appear to
increase the risk of hip/femur fracture (ORadj 0.83 [95% CI
0.42, 1.65]; Table 4). The risk associated with current use of
conventional antipsychotics (ORadj 1.76 [95% CI 1.48,
2.08]) was increased, however, and was significantly greater
than with the use of atypical antipsychotics (p=0.038).
Table 5 presents the ORs for hip/femur fracture accord-
ing to the pharmacological profile of the antipsychotic in
current use. The use of antipsychotics with high prolactin-
raising properties (i.e., most conventional antipsychotics
and risperidone >4 mg/day) was associated with an
increased risk of hip/femur fracture (ORadj 1.75 [95% CI
1.48, 2.08]), whereas antipsychotics with low prolactin-
raising properties (i.e., most atypical antipsychotics includ-
ing risperidone ≤4 mg/day) were not associated with an
increased risk of fracture (ORadj 0.91 [95% CI 0.45, 1.85)].
After comparison of both groups, no significant difference
was observed. Analysis stratifying current use according to
the EPS properties of the antipsychotics suggested a trend
towards increased risk with increasing EPS (ORadj 1.55
[95% CI 1.18, 2.04] for low EPS and ORadj 1.97 [95% CI
1.49, 2.61] for high EPS), but this trend did not reach
statistical significance. There was no apparent association
Fig. 1 The risk of hip/femur fracture with duration of continuous
antipsychotic use (years) before the index date among current users
Table 4 Risk of hip/femur fracture with current antipsychotic use according to class and type of antipsychotic
Antipsychotic usea Cases Controls Univariate analysis Multivariate analysisb
(n=6,763) (n=26,341) OR (95% CI) OR (95% CI)
No use 6,105 24,770 Referent Referent
Past use 249 653 1.57 (1.35, 1.83) 1.33 (1.14, 1.56)
Recent use 172 425 1.63 (1.36, 1.96) 1.38 (1.15, 1.66)
Current use 237 493 2.00 (1.70, 2.35) 1.68 (1.43, 1.99)
Conventional antipsychoticsc 227 453 2.08 (0.48, 1.86) 1.76 (1.48, 2.08)d
Pipamperone 70 165 1.71 (1.29, 2.28) 1.54 (1.15, 2.06)
Haloperidol 75 106 2.87 (2.13, 3.86) 2.33 (1.72, 3.18)
Zuclopenthixol 38 56 2.78 (1.83, 4.21) 2.44 (1.59, 3.75)
Thioridazine 7 17 1.59 (0.64, 3.93) 1.51 (0.60, 3.78)
Levomepromazine 8 27 1.01 (0.45, 2.28) 0.80 (0.35, 1.82)
Others 34 96 1.39 (0.93, 2.07) 1.19 (0.79, 1.78)
Atypical antipsychoticsc 11 44 0.95 (0.48, 1.86) 0.83 (0.42, 1.65)d
Risperidone 8 32 0.95 (0.43, 2.10) 0.84 (0.38, 1.88)
Quetiapine, olanzapine, clozapine 3 12 0.93 (0.26, 3.34) 0.83 (0.23, 3.02)
a If more than one antipsychotic had been dispensed before the index date, then all dispensings were taken into account. For current, recent, and
past users, the last antipsychotic was dispensed respectively within 30 days, between 31 and 182 days, and more than 182 days prior to the index
date
b Adjusted for confounders as presented in Table 3
c In both the univariate as is the multivariate analysis also adjusted for other antipsychotics
d Significant difference between conventional antipsychotics and atypical antipsychotics (p=0.038 after Wald test).
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between the degree of potential orthostatic hypotensive or
sedative side effects and the risk of hip/femur fracture.
Discussion
The findings of this study have demonstrated an increased
risk of hip/femur fracture with the use of antipsychotics.
The risk was highest for current users, especially the most
elderly. The use of conventional antipsychotics appeared to
account for the increased risk, and there was evidence for
an increased risk with prolactin-raising antipsychotics and
those with greater potential to affect the extrapyramidal
system. We did not find evidence to support an association
between the average daily dose of antipsychotic and the
risk of hip/femur fracture.
Our findings confirm an association described in other
epidemiological studies on the risk of hip/femur fracture
with the use of antipsychotics [13–19]. The 1.7-fold
increased risk of fracture among current users and declining
risk after discontinuation of use agrees with the findings of
others. Hugenholtz et al. [18] reported a 1.3-fold increased
adjusted risk of fracture among current users who had been
using antipsychotics long term, and produced a plot similar
to ours for risk with cumulative days of treatment (Fig. 1).
Ray et al. [16] reported a doubling of risk among current
users (OR 2.0 [95% CI 1.6, 2.6]), although that risk
estimate may have been reduced with adjustment for more
potential confounding variables.
In agreement with other recent studies, we did not find
an association between the average daily dose of antipsy-
chotic and the risk of hip/femur fracture for current users
[17, 18]. Vestergaard et al. [17] described a dose–response
relationship for all users of antipsychotics before the index
date but the association was not apparent for current users
and the elapsed time between the last dispensing and the
index date could have been as much as 4 years. Although
we found a higher fracture risk for men currently using
antipsychotics, the difference between the sexes was not
significant. A greater fracture risk for men using antipsy-
chotics has been reported before [13], however, which
could reflect the effects of antipsychotic use and physio-
logical processes promoting bone loss [9].
The association between the risk of hip/femur fracture
and the EPS and prolactin-raising properties of the
antipsychotic prescribed could explain the shape of curve
derived by plotting the OR for fracture risk against the
duration of antipsychotic use (Fig. 1). The symptoms
associated with extrapyramidal effects often start soon after
the initiation of treatment and may be transient [35]. In
addition, the sedative and orthostatic hypotensive side
effects of antipsychotics often occur immediately after the
start of treatment. The second period of increased risk after
several months of use may reflect the effects of long-term
Table 5 Risk of hip/femur fracture with current antipsychotic use according to the pharmacological properties
Antipsychotic usea Cases Controls Univariate analysis Multivariate analysisb
(n=6,763) (n=26,341) OR (95% CI) OR (95% CI)
No use 6,105 24,770 Referent Referent
Past use 249 653 1.57 (1.35, 1.83) 1.33 (1.14, 1.56)
Recent use 172 425 1.63 (1.36, 1.96) 1.38 (1.15, 1.66)
Current use 237 493 2.00 (1.70, 2.35) 1.68 (1.43, 1.99)
Sedative properties
Low 89 144 2.54 (1.95, 3.31) 2.09 (1.59, 2.74)
Medium 53 125 1.78 (1.28, 2.47) 1.50 (1.07, 2.10)
High 95 224 1.75 (1.37, 2.24) 1.51 (1.17, 1.94)
EPS properties
Low 80 191 1.73 (1.33, 2.26) 1.55 (1.18, 2.04)
Medium 74 163 1.90 (1.44, 2.51) 1.58 (1.18, 2.10)
High 83 139 2.46 (1.87, 3.24) 1.97 (1.49, 2.61)
Prolactin properties
Non-raising 10 39 1.06 (0.52, 2.12) 0.91 (0.45, 1.85)
Raising 227 454 2.08 (1.76, 2.45) 1.75 (1.48, 2.08)
Orthostatic hypotensive properties
Low 97 157 2.55 (1.98, 3.29) 2.08 (1.60, 2.71)
Medium 92 257 1.49 (1.17, 1.90) 1.27 (0.99, 1.64)
High 48 79 2.50 (1.74, 3.59) 2.19 (1.51, 3.18)
aWhen more than one antipsychotic was dispensed simultaneously before the index date, then the antipsychotic with the most severe side effect
was selected. For current, recent, and past users, the last antipsychotic was dispensed respectively within 30 days, between 31 and 182 days, and
more than 182 days prior to the index date
b Adjusted for confounders as before
1504 Osteoporos Int (2009) 20:1499–1506
hyperprolactinemia on bone density. Indeed, Hugenholtz et
al. [20] found an increased risk only among long-term users
of antipsychotics and attributed this to the prolactin-raising
properties of antipsychotics. We did not find an association
between the sedative and orthostatic hypotensive side
effects and fracture risk in our analyses.
One of the strengths of our study is the size of the study
population (6,763 cases and 26,341 controls) and that it is
representative for the general population of the Netherlands,
although the absolute number of users of atypical anti-
psychotics was low. All prescribing information was
collected routinely and we do not expect our findings to
be biased with regards to exposure status. Also, as fractures
invariably result in hospitalization, we are confident that
cases, controls, and index dates were identified reliably.
Nevertheless, given the observational nature of this study,
the results should be interpreted with knowledge of its
limitations. First, cases and controls were not matched on
the period of observation available in the database and the
results could be affected by information bias. However, the
exclusion of patients with less than 1 year of follow-up did
not affect the results substantially. Second, information
about relevant diagnoses and co-morbidities may have been
recorded upon hospitalization for a fracture and it is likely
that the information available for cases was more complete
and up-to-date than that available for controls. It could be
argued that we did not consider the use of bisphosphonates
as a potential confounder. However, there should be a
priori evidence, that a confounder is associated both with
antipsychotic exposure and hip fracture risk. As far as we
know, there is no clear evidence that antipsychotic users
are more likely to be exposed to bisphosphonates,
compared to non-users. Moreover, in a case–control study,
the use of bisphosphonates may act as an intermediate
variable between exposure and outcome, rather than a
confounder. This is supported by the positive association
between bisphosphonate use and hip fracture (crude OR
1.71 [95% CI 1.47, 1.99], Table 2). Another potential
limitation is the unavailability of data on smoking and
alcohol consumption for a population that may include
individuals with high levels of nicotine and/or alcohol
consumption. Both are well-known risk factors of fracture
risk [36, 37]. The possibility remains, therefore, that
missing data on alcohol and smoking habit could
(partially) explain the positive association between anti-
psychotic use and fracture risk.
Finally, the comparison between conventional and
atypical antipsychotics should be interpreted with caution,
because the analyses in the group of atypical antipsychotic
users are based on a limited number of patients. Further-
more, atypical antipsychotics were introduced later into
clinical use than typical antipsychotics, which may have led
to different fracture risk profiles. Further studies are
required to confirm these results. The same applies for the
results regarding the prolactin-raising properties.
Confounding by indication is an alternative explanation for
the observed association between use of antipsychotics and
risk of hip fracture. The PHARMO database does not contain
routinely collected information on, for example, cognitive
disorders andmental illnesses for the majority of their patients.
Schizophrenia has been associated with perturbations in bone
metabolism [10]. However, a study among >3,600 Finnish
institutionalized elderly (mean age 83 years) showed that
only 4% were diagnosed with schizophrenia, whereas 58%
suffered from dementia, and 16% suffered from depression.
A substantial number (41%) of patients with dementia or
depression were prescribed antipsychotics. Furthermore, of
11–30% of all patients who had behavioral problems such as
wandering, being physically or verbally abusive, or who
resisted care, 48–64% were prescribed an antipsychotic at
least once a year [38]. Jeste et al. confirmed that anti-
psychotics are often prescribed off-label for behavioral
disturbances associated with dementia [39]. Because demen-
tia [40, 41] and depression [42] are risk factors for fractures,
they may be an alternative explanation for the positive
association between antipsychotic use and risk of hip/femur
fracture. This hypothesis is in line with the findings of
Bolton et al. who investigated antipsychotic use and the risk
of fractures, but found no increased risk among both
conventional and atypical antipsychotic users. In this study,
the results were adjusted for a wide range of confounders
including dementia, schizophrenia, and depression [43].
In conclusion, our findings support an increased risk for
fracture of the hip or femur for individuals prescribed
antipsychotics. There was a difference in fracture risk with
the use of atypical versus conventional antipsychotics,
wherein patients using conventional antipsychotic drugs had
an increased risk of hip/femur fracture. However, it should be
noted that the numbers of atypical antipsychotic users were
small, and that this observation needs further attention in other
study populations. We did not find a relationship between
average daily dose of antipsychotic and fracture risk. While
the possibility remains that the underlying disease or behavior
caused any increased risk of hip/femur fractures, our findings
may provide important information for prescribers, especially
those managing elderly and vulnerable patients.
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